Georgijević Ana, Tomić Z
Srp Arh Celok Lek. 2007 Nov-Dec;135 11-12:629-34. doi: 10.2298/sarh0712629g.
Photodynamic therapy (PDT) is a method of treatment of choroidal neovascularization (CNV) with a diode laser used after intravenously administered verteporfin. Verteporfin is a light-activated drug initiating photochemical reactions in the target tissue. This leads to the selective occlusion of blood vessels in the CNV with no damage of photoreceptors, retinal pigment epithelium and retinal blood vessels.
To show the results of the treatment of predominantly classic subfoveal CNV with PDT with verteporfin used for the first time in our country.
From 2003 to 2005, we treated 15 eyes in 15 patients using PDT and verteporfin, because of predominantly classic subfoveal CNV. If macular oedema was present as proved by fluorescein angiography, triamcinolone was administered intravitreally after FDT. Average follow-up period was 7 months (3 months to 2 years).
retrospective, noncomparative, consecutive case series.
Two thirds of patients had CNV due to AMD, while in others it was caused by pathologic myopia, chorioretinitis, angioid streaks, choroidal hemangioma, except for one patient who had idiopathic CNV. Visual acuity was stabile in 60% (9/15) of patients, of whom in 60% (6/10) of patients with AMD, as well as in patients with pathologic myopia, idiopathic CNV and choroidal hemangioma. Retreatment with PDT was indicated in 40% (6/15) and in 50% (5/10) of patients with AMD, mostly 4-6 months after first PDT, but was done only in one patient (economic reasons). In two patients with AMD, triamcinolone was administered intravitreally for 2-4 months, which resulted in the stabilization of visual acuity.
Visual acuity was stabile in 60% of all treated patients with predominantly classic subfoveal CNV after only one application of PDT with verteporfin during the average follow-up of 7 months (3 months to 2 years). Retreatment was indicated in 40% of the treated patients, and in 50% of patients with AMD. As confirmed, intravitreal administration of triamcinolone after PDT could stabilize visual acuity. Side effects were not noticed.
光动力疗法（PDT）是一种治疗脉络膜新生血管（CNV）的方法，使用静脉注射维替泊芬后，再用二极管激光进行治疗。维替泊芬是一种光激活药物，可在靶组织中引发光化学反应。这会导致选择性阻塞CNV中的血管，而不会损伤光感受器、视网膜色素上皮和视网膜血管。
展示在我国首次使用维替泊芬进行PDT治疗主要为经典型中心凹下CNV的结果。
2003年至2005年，由于主要为经典型中心凹下CNV，我们对15例患者的15只眼使用PDT和维替泊芬进行治疗。如果荧光素血管造影证实存在黄斑水肿，则在FDT后玻璃体内注射曲安奈德。平均随访期为7个月（3个月至2年）。
回顾性、非对照、连续病例系列。
三分之二的患者CNV由年龄相关性黄斑变性（AMD）引起，而其他患者则由病理性近视、脉络膜视网膜炎、血管样条纹、脉络膜血管瘤引起，除1例特发性CNV患者外。60%（9/15）的患者视力稳定，其中AMD患者的60%（6/10）以及病理性近视、特发性CNV和脉络膜血管瘤患者视力稳定。40%（6/15）的患者需要再次进行PDT治疗，AMD患者中有50%（5/10）需要再次治疗，大多在首次PDT治疗后4 - 6个月，但仅1例患者进行了再次治疗（经济原因）。2例AMD患者玻璃体内注射曲安奈德2 - 4个月，这使视力得以稳定。
在平均7个月（3个月至2年）的随访期内，仅一次使用维替泊芬进行PDT治疗后，60%主要为经典型中心凹下CNV的所有治疗患者视力稳定。40%的治疗患者需要再次治疗，AMD患者中有50%需要再次治疗。经证实，PDT后玻璃体内注射曲安奈德可稳定视力。未观察到副作用。
